Salubris Biotherapeutics Receives EMA Approval to Launch Phase 1 Clinical Trial of 5T4-Targeted ADC JK06 in Solid Tumors

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company focused on developing innovative biologic therapeutics, announced today that it has received approval from the European Medicines Agency (EMA) to commence a…

Read MoreSalubris Biotherapeutics Receives EMA Approval to Launch Phase 1 Clinical Trial of 5T4-Targeted ADC JK06 in Solid Tumors